SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.45 CNY | +0.84% |
|
-0.05% | -14.63% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -14.63% | 1.94B | - | ||
| -6.23% | 180B | C+ | ||
| +2.59% | 112B | C | ||
| -2.75% | 68.53B | A | ||
| +5.32% | 51.97B | B- | ||
| +7.61% | 44.08B | B- | ||
| +5.62% | 42.23B | B+ | ||
| +25.17% | 32.43B | B | ||
| +16.72% | 26.39B | A- | ||
| -2.66% | 24.97B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6826 Stock
- 688366 Stock
- Ratings Shanghai Haohai Biological Technology Co., Ltd.